Ozmosi | CT-P10 Drug Profile

Product Description

CT-P10 (Truximaª) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28497220/)

Mechanisms of Action: CD20 Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Celltrion
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ACTRN12622000306718p	2006-7041-83/hah	N/A	Not yet recruiting	Dental Caries\|Intestinal Diseases	2022-02-28
NCT05052528	UCDCC#299	P1	Unknown status	Diffuse Large B-Cell Lymphoma	2025-05-15	2026-06-04	Primary Endpoints
NCT02960646	NCI-2016-01915	P1	Completed	Myelodysplastic Syndrome\|Myeloproliferative Disorders\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Monocytic Leukemia\|Acute Myeloid Leukemia\|Acute Myelomonocytic Leukemia\|Chronic Myelomonocytic Leukemia\|Juvenile Myelomonocytic Leukemia,\|Blast Crisis\|Lymphocytic Chronic B-Cell Leukemia\|Leukemia, Plasma Cell\|Lymphoma, B-Cell\|Lymphoma, Non-Hodgkin\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Anemia, Aplastic\|Chronic Lymphoid Leukemia\|Preleukemia\|Chronic Myeloid Leukemia\|Multiple Myeloma\|Acute Lymphoid Leukemia	2023-02-13	2023-02-18	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT03432741	MC1689	P1	Terminated	B-Cell Marginal Zone Lymphoma\|Lymphoma, Non-Hodgkin\|Breast Cancer\|Mycosis Fungoides\|Adenocarcinoma\|T-Cell Cutaneous Lymphoma	2022-08-26	2025-05-28	Primary Completion Date\|Primary Endpoints\|Treatments
NCT01619761	NCI-2012-02071	P1	Unknown status	Lymphoma, B-Cell\|Myelodysplastic Syndrome\|Lymphocytic Chronic B-Cell Leukemia\|Leukemia, Plasma Cell\|Chronic Lymphoid Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia\|Biphenotypic Acute Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Acute Myeloid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin\|Myeloid, Accelerated Leukemia\|Chronic Myeloid Leukemia\|Preleukemia\|Multiple Myeloma	2021-11-01	2022-02-02	Primary Endpoints\|Treatments\|Trial Status
NCT02779283	IRB00011766	P1	Completed	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia\|Acute Myeloid Leukemia	2018-04-19	2025-02-07	Primary Endpoints\|Treatments
NCT01873443	CT-P10 1.3	P1	Completed	Arthritis, Rheumatoid	2014-10-01	2019-03-19	Treatments
NCT02727803	NCI-2016-00584	P2	Recruiting	Anemia, Refractory, with Excess of Blasts\|Acute Myelomonocytic Leukemia\|Lymphoma, Non-Hodgkin\|Acute Lymphoid Leukemia\|Biphenotypic Acute Leukemia\|Multiple Myeloma\|Chronic Myeloid Leukemia\|Myelodysplastic-Myeloproliferative Diseases\|Myeloproliferative Disorders\|Chronic Myelomonocytic Leukemia\|Lymphoma, B-Cell\|Acute Monocytic Leukemia\|B-Cell Leukemia\|Chronic Lymphoid Leukemia\|Myeloid, Accelerated Leukemia\|Preleukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Myeloid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Myelodysplastic Syndrome\|Leukemia, Plasma Cell\|Juvenile Myelomonocytic Leukemia,	2027-05-31	2025-05-10	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT06834373	MC230813	P2	Recruiting	Lymphoma, Non-Hodgkin\|Inflammation\|T-Cell Cutaneous Lymphoma\|Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma	2027-03-03	2025-04-05	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT03096782	NCI-2018-01236	P2	Completed	Myelodysplastic Syndrome\|Lymphoma, B-Cell\|Anemia, Refractory, with Excess of Blasts\|Lymphoma, Non-Hodgkin\|Acute Myelomonocytic Leukemia\|Preleukemia\|Chronic Myeloid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Acute Lymphoid Leukemia\|Chronic Myelomonocytic Leukemia\|Myeloid, Accelerated Leukemia\|Acute Myeloid Leukemia\|Biphenotypic Acute Leukemia\|Acute Monocytic Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Hodgkin Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Lymphoid Leukemia\|Histiocytosis, Langerhans-Cell	2022-09-20	2023-06-30	Primary Endpoints
NCT05457556	ASCT2031	P3	Active, not recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myelodysplastic Syndrome\|Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Preleukemia	2026-06-30	2025-05-06	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT02003222	NCI-2013-02229	P3	Active, not recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2023-06-23	2025-02-07	Primary Endpoints\|Treatments
2014-005324-10	2014-005324-10	P3	Completed	Follicular Lymphoma	2019-09-04	2025-05-06	Treatments
2013-004493-96	2013-004493-96	P3	Completed	Follicular Lymphoma	2018-12-29	2022-03-13	Treatments
NCT02260804	CT-P10 3.4	P3	Completed	Follicular Lymphoma	2018-01-04	2021-04-09	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT02162771	rituximab	P3	Completed	Follicular Lymphoma	2016-01-12	2020-01-30	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date
NCT02149121	rituximab	P3	Completed	Arthritis, Rheumatoid	2016-01-01	2021-12-17	Primary Endpoints\|Treatments
2011-002813-12	2011-002813-12	P3	Terminated	Follicular Lymphoma	2013-09-30	2022-03-13	Treatments

Recent News Events

Date	Type	Title
04/14/2021	News Article	Global Biosimilar Monoclonal Antibodies Forecast 2020-2030
04/10/2020	News Article	Visiongain Report Provides Critical Market-led Data on the $6.6bn Biosimilar Monoclonal Antibodies Market
07/18/2019	News Article	Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

CT-P10

Alternative Names: ct-p10, ctp10, ct p10 Clinical Status: Inactive Latest Update: 2026-06-23 Latest Update Note: Clinical Trial Update